

January 30, 2023

To The Manager, Listing Department National Stock Exchange of India Limited Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: BLISSGVS	To The General Manager, Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 506197
---	--

Dear Sir/Madam,

Subject: Newspaper Advertisement of Unaudited Financial Results for the quarter and nine months ended December 31, 2022

Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper advertisement of Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshakti' a Regional Daily, on January 26, 2023.

Kindly take the same on record.

Thanking you.

Yours faithfully,
For **Bliss GVS Pharma Limited**


Aditi Bhatt
Company Secretary



Encl: as above

Regd. Office : 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory : Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.
Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

SC Seeks RBI View on Steps to Tackle NPAs

Apex court wants to know if regulator could implement panel recommendations

indu.bhan@timesgroup.com

New Delhi: The Supreme Court on Wednesday asked the Reserve Bank of India to inform it about the steps the banking regulator could take to implement a high-level committee's recommendations to tackle bad loans.

A bench led by Justice Sanjay K Kaul gave four weeks for the RBI to file its reply. The direction came after the RBI said it had accepted the recommendations of the five-member committee, constituted by the government to study banking reforms.

Among its suggestions on recovering non-performing assets, the committee in 2017 said banks must publish on their websites the list of defaulters whose names are already in public domain or where recovery proceedings are initiated under the

HC Asks RBI, Govt to Ensure Compliance by Lending Apps



NEW DELHI: The Delhi High Court (HC) has directed RBI and the central government to ensure that digital lending platforms strictly comply with the regulatory framework that was put in place last year to check exorbitant interest rates and harassment of borrowers by recovery agents. A bench of Chief Justice Satish Chandra Sharma and Justice Subramonium Prasad also asked the government to take immediate steps on the recommendations submitted by the RBI's working group on digital lending. — **Indu Bhan**

Surfaces Act. It said promoters should be personally made liable for any siphoning off of funds. Instructions are being issued mandating banks to examine and take a view on classifying an account as a case of wilful default or not within 60 days of it becoming an NPA (where the exposure is more than ₹50 crore), the RBI said in an affidavit.

The central bank said it was expanding the definition of wilful defaulters to include borrowers who had committed to infusing equity but eventually failed to do so. It is also exploring the feasibility of banks using data from the

Central Repository of Information on Large Credits to gather information on the group entities of borrowers. The RBI claimed that its efforts had resulted in a material decline in NPAs. During the hearing, Justice Kaul commented: "We have to balance the issue of public money and seeing that the ending procedure is not too cumbersome... We have seen many cases where nothing happens, those who had invested were left high and dry."

The judge said priority should be on cases where the amount is huge.

AIRCRAFT-TO-GROUND COMMUNICATION

Telcos Split over Spectrum Allocation to Airlines

Our Bureau

Mumbai: Telcos are divided on how to allocate spectrum for aircraft to ground station data communication services provided by entities other than the Airports Authority of India (AAI). While all three operators agreed under the licensing regime, Reliance Jio and Vodafone Idea want the allocation to be through an auction. Bharati Airtel, on the other hand, wants the

current mechanism of assignment through an administrative basis — or on payment of a fee — to continue.

The carriers were responding to the Telecom Regulatory Authority of India's (Trai's) consultation paper, where it had asked for suggestions regarding the mechanism of providing these airwave services to IT and communication vendors to the Indian aviation industry — Société Internationale de Télécommunications Aéronautiques (SITA) and Bird Consultancy Services (BCS).

"Considering spectrum is a valuable



and inexhaustible natural resource as well as having elements of public good, we believe that it is vital to ensure effi-

ent management and use of the spectrum as well as no loss to the national exchequer," Vodafone Idea said.

It added that since the spectrum is being given for commercial services to a commercial entity, "it should be allocated through a transparent and open auction process"

Jio said that aircraft to ground communication is a critical telecommunication service for aircraft and passenger safety but currently operates on adhoc permission-approval methodology.



BLISS GVS PHARMA LIMITED

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakinaka Road, Andheri (East), Mumbai - 400 072.

Tel: 022-42160000 • Fax: 022-28563930 • Email: info@blissgvs.com • Website: www.blissgvs.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED	QUARTER ENDED		NINE MONTHS ENDED		YEAR ENDED		
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022
	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
Total Income from Operations (net)	18,021.48	15,307.98	19,690.67	49,920.80	51,824.75	66,898.46	21,136.35	17,458.10	22,229.42	58,161.70	59,969.42	77,894.60
Profit before Tax and Exceptional Item	3,989.06	3,529.20	3,366.80	10,724.85	9,748.24	12,365.52	4,743.28	2,019.06	3,473.33	10,682.19	10,130.56	12,775.98
Profit before Tax	3,989.06	3,529.20	3,641.31	10,724.85	10,022.75	12,640.03	4,743.28	2,019.06	(3,886.12)	10,682.19	2,771.11	5,416.53
Net Profit for the period	2,928.00	2,544.68	2,717.38	7,937.20	7,355.92	9,266.40	2,978.83	1,600.19	(4,853.10)	7,326.99	(34.04)	2,312.65
Total Comprehensive Income for the period	2,915.78	2,475.01	2,728.82	7,879.72	7,368.37	9,296.67	3,841.73	1,429.23	(4,771.15)	7,844.42	(10.77)	1,571.79
Equity Share Capital	1,041.53	1,038.85	1,036.78	1,041.53	1,036.78	1,036.78	1,041.53	1,038.85	1,036.78	1,041.53	1,036.78	1,036.78
Other Equity	91,966.07	88,950.43	82,059.84	91,966.07	82,059.84	84,106.29	88,076.80	84,311.06	79,511.26	88,076.80	79,511.26	80,833.39
Earnings Per Share (Not annualised)												
i. Basic (₹)	2.81	2.45	2.62	7.63	7.09	8.97	2.68	1.33	(4.83)	6.49	(0.44)	1.46
ii. Diluted (₹)	2.76	2.41	2.57	7.51	6.96	8.81	2.64	1.31	(4.74)	6.39	(0.43)	1.43

Note:

(1) The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Nine months ended December 31, 2022 and Annual Result for the Year ended March 31, 2022 are filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The figures for the quarter ended December 31, 2022 are the balancing figures between unaudited figures in respect of the nine months ended December 31, 2022 and the year to date published figures for the half year ended September 30, 2022.

(2) The full format of the Standalone and Consolidated financial results for the Quarter and Nine months ended December 31, 2022 and Annual Result for the Year ended March 31, 2022 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.

(3) The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.

(4) During the Quarter and Nine months ended December 31, 2021 and Year ended March 31, 2022, with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD 3,75,000 vide agreement dated 25th Nov, 2021 and is derecognised in the year ended March 31, 2022, though the consideration is received on January 5, 2022 and the concerned shares were transferred on January 12, 2022.

(5) During the Quarter and Nine months ended December 31, 2021 and Year ended March 31, 2022, standalone financials statements includes exceptional item ₹ 274.51 Lakh, being profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore.

For BLISS GVS PHARMA LIMITED

SD/-

GAGAN HARSH SHARMA
MANAGING DIRECTOR
Din No : 07939421

Place : Mumbai
Date : January 24, 2023

Office of the Director General, Medical Education and Training, Uttar Pradesh

6th Floor, Jawahar Bhawan, Ashok Marg, Lucknow (UP)-226001

Email:- dgmededu@gmail.com
Website:- www.dgme.up.gov.in

Phone: 0522-2287653
Fax: 0522-2288193

No:- ME-2/2023/109 Lucknow: Dated: 24 January, 2023

Advertisement For the Post of Principal

In lieu of the letter No.23/71-3-2023 Dated 06 January, 2023 of Government of Uttar Pradesh, applications are invited on prescribed format from Indian Nationals for the post of Principal (one post) for each Autonomous State Medical College, Ayodhya, Shahjahanpur, Mirzapur, Basti and Etah having the following educational qualifications and experience -

- Age:-** The candidate must have attained the minimum age of 50 years and maximum age of 62 years on the 01st July, 2023.
- He shall be a person of eminent medical and administrative experience.
- Educational Qualifications:-**

"He shall possess the recognized postgraduate medical qualification and other academic qualifications from a recognized institution with a minimum of ten years' teaching experience as Professor/Associate Professor/Reader in a medical College/Institutes, out of which at least five years should be as Professor in a department.

Preference for this appointment will be given to the Head of the Department of medical college/Institute."

4- Pay Scale:-

For the post of Principal the scale of pay would be Academic Level -14, Entry pay- Rs. 1,44,200/- which has been fixed for principal of Government Medical Colleges as pay and allowances etc by The State Government.

5- Application Fee:-

A demand draft of Rs. 1000/- (Rs. One thousand only) payable in favour of "Director General Medical Education and Training, U.P. Lucknow" payable at Lucknow is mandatory as application fee.

6- If applying for more than one place candidate should send separate application for each Autonomous State Medical College with requisite document & Bank Demand Draft.

7- Those candidates, who have already applied for the advertisement no ME-2/2022/959 Dated 02 May, 2022 need not to apply again for the post of Principal. Interested Candidates are invited to send their application on prescribed format (downloadable from www.dgme.up.gov.in) along with certificates latest by 05:00 pm on 24.02.2023, to the Office of Director General, Medical Education and Training,



BLISS GVS PHARMA LIMITED

CIN No.- L24230MH1984PLC034771

Registered Office: 102, Hyde Park, Sakinaka Road, Andheri (East), Mumbai - 400 072.
• Tel: 022-42160000 • Fax: 022-28563930 • Email: info@blissgvs.com • Website: www.blissgvs.com

EXTRACT OF STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

Particulars	STANDALONE						CONSOLIDATED						(₹ in Lakhs)
	QUARTER ENDED			NINE MONTHS ENDED			QUARTER ENDED			NINE MONTHS ENDED			YEAR ENDED
	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021	31.03.2022	
	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED	
Total Income from Operations (net)	18,021.48	15,307.98	19,690.67	49,920.80	51,824.75	66,898.46	21,136.35	17,458.10	22,229.42	58,161.70	59,969.42	77,894.60	
Profit before Tax and Exceptional Items	3,989.06	3,529.20	3,366.80	10,724.85	9,748.24	12,365.52	4,743.28	2,019.06	3,473.33	10,682.19	10,130.56	12,775.98	
Profit before Tax	3,989.06	3,529.20	3,641.31	10,724.85	10,022.75	12,640.03	4,743.28	2,019.06	(3,886.12)	10,682.19	2,771.11	5,416.53	
Net Profit for the period	2,928.00	2,544.68	2,717.38	7,937.20	7,355.92	9,266.40	2,978.83	1,600.19	(4,853.10)	7,326.99	(34.04)	2,312.65	
Total Comprehensive Income for the period	2,915.78	2,475.01	2,728.82	7,879.72	7,368.37	9,296.67	3,841.73	1,429.23	(4,771.15)	7,844.42	(10.77)	1,571.79	
Equity Share Capital	1,041.53	1,038.85	1,036.78	1,041.53	1,036.78	1,036.78	1,041.53	1,038.85	1,036.78	1,041.53	1,036.78	1,036.78	
Other Equity	91,966.07	88,950.43	82,059.84	91,966.07	82,059.84	84,106.29	88,076.80	84,311.06	79,511.26	88,076.80	79,511.26	80,533.39	
Earnings Per Share (Not annualised)													
I. Basic (₹)	2.81	2.45	2.62	7.63	7.09	8.97	2.68	1.33	(4.83)	6.49	(0.44)	1.46	
II. Diluted (₹)	2.76	2.41	2.57	7.51	6.96	8.81	2.64	1.31	(4.74)	6.39	(0.43)	1.43	

Note:

- The above is an extract of the detailed format of the Standalone and Consolidated financial results for the Quarter and Nine months ended December 31, 2022 and Annual Result for the Year ended March 31, 2022 are filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The figures for the quarter ended December 31, 2022 are the balancing figures between unaudited figures in respect of the nine months ended December 31, 2022 and the year to date published figures for the half year ended September 30, 2022.
- The full format of the Standalone and Consolidated financial results for the Quarter and Nine months ended December 31, 2022 and Annual Result for the Year ended March 31, 2022 are available on the Stock Exchange websites- www.bseindia.com and www.nseindia.com and on the Company's website www.blissgvs.com.
- The results have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act read with relevant rules issued there under.
- During the Quarter and Nine months ended December 31, 2021 and Year ended March 31, 2022, with respect to consolidated financials statements, exceptional items represent impairment of trade receivable pertaining to a wholly owned subsidiary Bliss GVS Clinic Health Care Pte Ltd, Singapore. The said subsidiary has been sold by the Company for a consideration of USD 3,75,000 vide agreement dated 25th Nov, 2021 and is derecognised in the year ended March 31, 2022, though the consideration is received on January 5, 2022 and the concerned shares were transferred on January 12, 2022.
- During the Quarter and Nine months ended December 31, 2021 and Year ended March 31, 2022, standalone financials statements includes exceptional item ₹ 274.51 Lakh, being profit on sale of a wholly owned subsidiary namely, Bliss GVS Clinic Health Care Pte Ltd, Singapore.

For BLISS GVS PHARMA LIMITED

SD/-
GAGAN HARSH SHARMA
MANAGING DIRECTOR
Din No : 07939421

Place : Mumbai
Date : January 24, 2023

